Business
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
CHICAGO, February 26, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Je
About this update from Torrent Pharmaceuticals Ltd
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":808,"height":274,"url":"https://media.zenfs.com/en/business-wire.com/5b7867841d4f48b53a3039eb065c89f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d0lO89cfUcu6rX.og_zB_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5b7867841d4f48b53a3039eb065c89f2","width":808,"height":274},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Wtxw1avm66wwevDRO_sFaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MTY7aD01NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5b7867841d4f48b53a3039eb065c89f2","width":808,"height":274}},"lazy":false},{"type":"text","content":"Four Orange Book Listed Patents through March 2040","length":50,"tagName":"p","attribs":{}},{"type":"text","content":"Orphan Drug Exclusivity through December 2028","length":45,"tagName":"p","attribs":{}},{"type":"text","content":"CHICAGO, February 26, 2026--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jersey against Torrent Pharmaceuticals Limited (along with its affiliate) and Somerset Therapeutics, LLC (along with its affiliates), each of which filed an Abbreviated New Drug Application ("ANDA") with the U.S. Food and Drug Administration (the "FDA") seeking approval to manufacture, use or sell a generic version of Recorlev® (levoketoconazole) (each, an "ANDA Filer"). Xeris’s complaint seeks an injunction to prevent the manufacture, use, and sale of a generic version of RECORLEV by each ANDA Filer until the expiration of Xeris’s patents in March 2040.","length":1105,"tagName":"p"},{"type":"text","content":""We are confident in the quality and strength of the intellectual property we have developed for Recorlev," said John P. Shannon, CEO of Xeris Biopharma. "We have filed this patent infringement lawsuit to vigorously defe...